News & Blog

Tag Archives: FDA

New Treatment Approved for Certain Glioma Patients

On June 22, 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new treatment combination that will now be available as an option for certain brain tumor patients. The FDA approved the combination of two oral drugs called dabrafenib (brand name: Tafinlar) and trametinib (brand name: Mekinist) for the treatment of […]

Innovating Brain Tumor Clinical Trials: Lessons Learned During the COVID-19 Experience

The global COVID-19 pandemic disrupted nearly every facet of life in 2020, and brain cancer research, particularly clinical trials, was not spared from its impacts. As is often the case, though, with disruption comes the opportunity to innovate. Convening key stakeholders across the brain tumor community, the National Brain Tumor Society (NBTS) has taken stock […]

National Brain Tumor Society Congratulates President-elect Joe Biden

National Brain Tumor Society (NBTS) offers our congratulations to President-elect Joe Biden and Vice President-elect Kamala Harris. President-elect Biden, more so than any other president in U.S. history, personally understands the devastating nature of brain tumors following the loss of his son, Beau, to glioblastoma. He and his wife, Dr. Jill Biden, care deeply about […]

Share